Humana Inc. (NYSE:HUM) Holdings Lifted by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. increased its holdings in shares of Humana Inc. (NYSE:HUM) by 2.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 67,672 shares of the insurance provider’s stock after purchasing an additional 1,715 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Humana were worth $17,169,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. State Street Corp grew its holdings in shares of Humana by 1.0% during the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock valued at $1,701,582,000 after buying an additional 53,272 shares in the last quarter. Pzena Investment Management LLC boosted its position in Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after purchasing an additional 1,103,132 shares during the last quarter. FMR LLC boosted its position in Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after purchasing an additional 643,291 shares during the last quarter. Sanders Capital LLC boosted its position in Humana by 1.0% during the third quarter. Sanders Capital LLC now owns 1,168,341 shares of the insurance provider’s stock valued at $370,060,000 after purchasing an additional 11,923 shares during the last quarter. Finally, Boston Partners boosted its position in Humana by 435.8% during the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock valued at $279,236,000 after purchasing an additional 893,637 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.37% of the company’s stock.

Humana Price Performance

NYSE HUM opened at $266.33 on Friday. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market capitalization of $32.14 billion, a PE ratio of 26.77, a P/E/G ratio of 2.05 and a beta of 0.57. The stock has a 50-day simple moving average of $271.33 and a 200 day simple moving average of $276.92.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Research analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.33%. Humana’s dividend payout ratio is 35.58%.

Wall Street Analyst Weigh In

HUM has been the subject of a number of research reports. Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Morgan Stanley reduced their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Barclays lifted their price objective on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. StockNews.com cut Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Finally, Truist Financial boosted their price target on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Eighteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.